Jeff Blue­stone just raised $265M to de­vel­op cu­ra­tive cell ther­a­pies. We asked him how

Jeff Blue­stone had some big goals in mind when he de­cid­ed to make a switch from a decades-long ca­reer in acad­e­mia and non-prof­it re­search to a biotech start­up CEO. And now — 18 months af­ter the $40 mil­lion launch par­ty — he has a whole lot more mon­ey on hand to pay for the con­sid­er­able amount of work ahead at Sono­ma Bio­ther­a­peu­tics.

This morn­ing Blue­stone is tak­ing the wraps off a $265 mil­lion B round af­ter boost­ing the core syn­di­cate of A-list in­vestors he start­ed with. Even by to­day’s stan­dards, that sum dwarfs the kind of $100 mil­lion-plus megarounds that have be­come stan­dard fare in biotech over the last 2 years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER